ES2693779T3 - Ciclesonida para el tratamiento de enfermedades de las vías respiratorias en caballos - Google Patents
Ciclesonida para el tratamiento de enfermedades de las vías respiratorias en caballos Download PDFInfo
- Publication number
- ES2693779T3 ES2693779T3 ES13811924.3T ES13811924T ES2693779T3 ES 2693779 T3 ES2693779 T3 ES 2693779T3 ES 13811924 T ES13811924 T ES 13811924T ES 2693779 T3 ES2693779 T3 ES 2693779T3
- Authority
- ES
- Spain
- Prior art keywords
- ciclesonide
- inhaler
- days
- respimat
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 title abstract description 51
- 229960003728 ciclesonide Drugs 0.000 title abstract description 49
- 241000283086 Equidae Species 0.000 title abstract description 18
- 208000023504 respiratory system disease Diseases 0.000 title abstract description 4
- 238000000034 method Methods 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 5
- 150000003839 salts Chemical class 0.000 abstract description 4
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 38
- 229960000257 tiotropium bromide Drugs 0.000 description 38
- 229960003957 dexamethasone Drugs 0.000 description 35
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 35
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 26
- 241000283073 Equus caballus Species 0.000 description 24
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 16
- 229960004436 budesonide Drugs 0.000 description 16
- 229960000890 hydrocortisone Drugs 0.000 description 13
- 230000002123 temporal effect Effects 0.000 description 12
- 230000002685 pulmonary effect Effects 0.000 description 10
- 230000004199 lung function Effects 0.000 description 8
- 230000000241 respiratory effect Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 238000000540 analysis of variance Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- -1 2-methyl-1-oxo-propoxy Chemical group 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010025327 Lymphopenia Diseases 0.000 description 2
- 206010029379 Neutrophilia Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000003434 inspiratory effect Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 231100001023 lymphopenia Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QIEPWCSVQYUPIY-LEKSSAKUSA-N Delta(1)-progesterone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 QIEPWCSVQYUPIY-LEKSSAKUSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229940099032 alvesco Drugs 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- OXPLANUPKBHPMS-ZXBNPROVSA-N desisobutyrylciclesonide Chemical compound C1([C@@H]2O[C@@H]3C[C@H]4[C@H]5[C@@H]([C@]6(C=CC(=O)C=C6CC5)C)[C@@H](O)C[C@@]4([C@@]3(O2)C(=O)CO)C)CCCCC1 OXPLANUPKBHPMS-ZXBNPROVSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940041682 inhalant solution Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- GKLVIAQLYSDWGM-YNDBTVFMSA-N methyl (1r,3as,4s,5r,8s,9ar)-8-[(1r,3as,4r,7ar)-7a-methoxycarbonyl-1,3a,4-trimethyl-7-oxo-1,2,3,4-tetrahydroinden-5-yl]-5-hydroxy-1,3a,4-trimethyl-9-oxo-1,2,3,4,5,6,7,8-octahydrocyclopenta[b]naphthalene-9a-carboxylate Chemical compound O=C1[C@@]2(C(=O)OC)[C@H](C)CC[C@@]2(C)[C@H](C)C([C@H](O)CC2)=C1[C@@H]2C([C@H]1C)=CC(=O)[C@]2(C(=O)OC)[C@@]1(C)CC[C@H]2C GKLVIAQLYSDWGM-YNDBTVFMSA-N 0.000 description 1
- 229940087154 omnaris Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000003918 potentiometric titration Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12199302 | 2012-12-21 | ||
| EP12199302 | 2012-12-21 | ||
| PCT/EP2013/077265 WO2014096115A1 (en) | 2012-12-21 | 2013-12-18 | Ciclesonide for the treatment of airway disease in horses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2693779T3 true ES2693779T3 (es) | 2018-12-13 |
Family
ID=47552829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13811924.3T Active ES2693779T3 (es) | 2012-12-21 | 2013-12-18 | Ciclesonida para el tratamiento de enfermedades de las vías respiratorias en caballos |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20140179651A1 (enExample) |
| EP (1) | EP2934479B1 (enExample) |
| AR (1) | AR094241A1 (enExample) |
| AU (2) | AU2013360691B2 (enExample) |
| BR (2) | BR122016029247A2 (enExample) |
| CA (1) | CA2888428C (enExample) |
| CY (2) | CY1121115T1 (enExample) |
| DK (1) | DK2934479T3 (enExample) |
| ES (1) | ES2693779T3 (enExample) |
| FR (1) | FR20C1026I1 (enExample) |
| HR (1) | HRP20181980T1 (enExample) |
| HU (1) | HUS2000020I1 (enExample) |
| IN (1) | IN2015DN02894A (enExample) |
| LT (2) | LT2934479T (enExample) |
| MA (1) | MA38169B2 (enExample) |
| MX (1) | MX368306B (enExample) |
| NO (1) | NO2020014I1 (enExample) |
| NZ (1) | NZ706573A (enExample) |
| PL (1) | PL2934479T3 (enExample) |
| PT (1) | PT2934479T (enExample) |
| RS (1) | RS57740B1 (enExample) |
| SI (1) | SI2934479T1 (enExample) |
| WO (1) | WO2014096115A1 (enExample) |
| ZA (1) | ZA201502288B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140057604A (ko) | 2011-08-12 | 2014-05-13 | 베링거잉겔하임베트메디카게엠베하 | 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제 |
| HRP20181980T1 (hr) | 2012-12-21 | 2019-01-25 | Boehringer Ingelheim Vetmedica Gmbh | Ciklezonid za liječenje dišnih puteva kod konja |
| ES2706757T3 (es) | 2012-12-21 | 2019-04-01 | Boehringer Ingelheim Vetmedica Gmbh | Formulación farmacéutica que comprende ciclesonida |
| WO2015193213A1 (en) | 2014-06-18 | 2015-12-23 | Boehringer Ingelheim Vetmedica Gmbh | Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses |
| US11191746B2 (en) * | 2016-10-14 | 2021-12-07 | Jeju National University Industry-Academic Cooperation Foundation | Composition for inhibiting a growth of cancer stem cells comprising ciclesonide |
| US20230033224A1 (en) * | 2020-01-10 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Ciclesonide for ameliorating quality of life (qol) in equines |
| EP4188327B1 (en) | 2020-07-31 | 2025-05-28 | Chemo Research, S.L. | Combination therapy for inhalation administration |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5954049A (en) | 1991-10-15 | 1999-09-21 | Trudell Medical Limited | Equine mask with MDI adapter |
| DE19536902A1 (de) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
| US5823179A (en) | 1996-02-13 | 1998-10-20 | 1263152 Ontario Inc. | Nebulizer apparatus and method |
| US6264923B1 (en) * | 1998-05-13 | 2001-07-24 | 3M Innovative Properties Company | Medicinal aerosol formulation of ciclesonide and related compounds |
| US6706726B2 (en) | 2000-10-14 | 2004-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anticholinergics which may be used as medicaments as well as processes for preparing them |
| DE10050994A1 (de) | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung |
| DE10062712A1 (de) | 2000-12-15 | 2002-06-20 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden |
| US6904908B2 (en) | 2002-05-21 | 2005-06-14 | Trudell Medical International | Visual indicator for an aerosol medication delivery apparatus and system |
| US7244742B2 (en) | 2002-08-17 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic |
| DE10237739A1 (de) | 2002-08-17 | 2004-02-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika |
| AU2003272450A1 (en) | 2002-09-13 | 2004-04-30 | C. Steven Smith | Novel composition and method for treatment of upper respiratory conditions |
| AU2004241746A1 (en) * | 2003-05-22 | 2004-12-02 | Nycomed Gmbh | Salmeterol and ciclesonide combination |
| US20050020692A1 (en) | 2003-07-24 | 2005-01-27 | Ciofalo Vincent B. | Treatment of heaves |
| WO2005025578A1 (en) | 2003-09-16 | 2005-03-24 | Altana Pharma Ag | Use of ciclesonide for the treatment of respiratory diseases |
| PE20050941A1 (es) * | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | Suspensiones acuosas de ciclesonida para nebulizacion |
| JP2007533706A (ja) | 2004-04-20 | 2007-11-22 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 喫煙患者における呼吸器疾患の治療のためのシクレソニドの使用 |
| EP1763344A1 (en) | 2004-06-29 | 2007-03-21 | Boehringer Ingelheim International GmbH | Medicaments for inhalation comprising steroids and an anticholinergic |
| DE102004056579A1 (de) | 2004-11-23 | 2006-05-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum, Salmeterol und ein Steroid |
| UY30543A1 (es) | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de beta- agonistas |
| UY30542A1 (es) | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de agonistas beta |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| BRPI1011813B1 (pt) | 2009-06-25 | 2020-08-04 | Boehringer Ingelheim Vetmedica Gmbh | Inalador |
| US7829748B1 (en) * | 2009-09-21 | 2010-11-09 | Honeywell International Inc. | Process for the manufacture of 1,3,3,3-tetrafluoropropene |
| WO2014007766A1 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhalers comprising a carrier other than lactose |
| EA201590030A1 (ru) | 2012-07-05 | 2015-09-30 | Арвен Айлак Санайи Ве Тиджарет А.С. | Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент |
| US9539408B2 (en) | 2012-10-31 | 2017-01-10 | Trudell Medical International | Nebulizer apparatus |
| HRP20181980T1 (hr) | 2012-12-21 | 2019-01-25 | Boehringer Ingelheim Vetmedica Gmbh | Ciklezonid za liječenje dišnih puteva kod konja |
| ES2706757T3 (es) | 2012-12-21 | 2019-04-01 | Boehringer Ingelheim Vetmedica Gmbh | Formulación farmacéutica que comprende ciclesonida |
| AR097394A1 (es) | 2013-08-20 | 2016-03-09 | Boehringer Ingelheim Vetmedica Gmbh | Inhalador |
| CA2913811C (en) | 2013-08-20 | 2022-06-07 | Boehringer Ingelheim Vetmedica Gmbh | Inhaler |
| WO2015193213A1 (en) | 2014-06-18 | 2015-12-23 | Boehringer Ingelheim Vetmedica Gmbh | Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses |
-
2013
- 2013-12-18 HR HRP20181980TT patent/HRP20181980T1/hr unknown
- 2013-12-18 US US14/132,580 patent/US20140179651A1/en not_active Abandoned
- 2013-12-18 AU AU2013360691A patent/AU2013360691B2/en active Active
- 2013-12-18 US US14/654,009 patent/US9918995B2/en active Active
- 2013-12-18 NZ NZ70657313A patent/NZ706573A/en unknown
- 2013-12-18 LT LTEP13811924.3T patent/LT2934479T/lt unknown
- 2013-12-18 DK DK13811924.3T patent/DK2934479T3/en active
- 2013-12-18 MX MX2015007947A patent/MX368306B/es active IP Right Grant
- 2013-12-18 PT PT13811924T patent/PT2934479T/pt unknown
- 2013-12-18 PL PL13811924T patent/PL2934479T3/pl unknown
- 2013-12-18 EP EP13811924.3A patent/EP2934479B1/en active Active
- 2013-12-18 ES ES13811924.3T patent/ES2693779T3/es active Active
- 2013-12-18 RS RS20181190A patent/RS57740B1/sr unknown
- 2013-12-18 BR BR122016029247-9A patent/BR122016029247A2/pt not_active Application Discontinuation
- 2013-12-18 MA MA38169A patent/MA38169B2/fr unknown
- 2013-12-18 SI SI201331266T patent/SI2934479T1/sl unknown
- 2013-12-18 CA CA2888428A patent/CA2888428C/en active Active
- 2013-12-18 WO PCT/EP2013/077265 patent/WO2014096115A1/en not_active Ceased
- 2013-12-18 IN IN2894DEN2015 patent/IN2015DN02894A/en unknown
- 2013-12-18 BR BR112015010842-3A patent/BR112015010842B1/pt active IP Right Grant
- 2013-12-20 AR ARP130104978A patent/AR094241A1/es not_active Application Discontinuation
-
2015
- 2015-04-07 ZA ZA2015/02288A patent/ZA201502288B/en unknown
-
2016
- 2016-10-13 US US15/292,765 patent/US10258634B2/en active Active
-
2018
- 2018-02-06 US US15/889,307 patent/US10441597B2/en active Active
- 2018-03-07 AU AU2018201642A patent/AU2018201642B2/en active Active
- 2018-11-09 CY CY181101189T patent/CY1121115T1/el unknown
-
2020
- 2020-06-12 NO NO2020014C patent/NO2020014I1/no unknown
- 2020-06-18 LT LTPA2020511C patent/LTPA2020511I1/lt unknown
- 2020-06-26 FR FR20C1026C patent/FR20C1026I1/fr active Active
- 2020-06-29 CY CY2020015C patent/CY2020015I2/el unknown
- 2020-06-29 HU HUS2000020C patent/HUS2000020I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Alabsi et al. | Nose-to-brain delivery of therapeutic peptides as nasal aerosols | |
| JP5863641B2 (ja) | 濃縮肥満細胞安定化用薬学的調合物 | |
| ES2762806T3 (es) | Tratamiento utilizando estabilizadores de mastocitos para trastornos sistémicos | |
| ES2988617T3 (es) | Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales | |
| US20120077786A1 (en) | Methods and compositions for disease treatment using inhalation | |
| HRP20230272T1 (hr) | Postupci za liječenje cistične fibroze | |
| EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
| RU2019100425A (ru) | Новая доза и препаративная форма | |
| CN106535889A (zh) | 用于治疗肺疾病的肥大细胞稳定剂 | |
| TW202615055A (zh) | 用於治療、改善或預防冠狀病毒感染之製品與方法 | |
| WO2017011729A1 (en) | Combination therapies for the treatment of lung diseases | |
| JP2013515022A (ja) | 相乗的抗ウイルス組成物及びその使用 | |
| US20230158259A1 (en) | Products of manufacture and methods for treating, ameliorating or preventing microbial infections | |
| US20230263725A1 (en) | Intranasal administration of an antioxidant compound for treating coronavirus infection | |
| BR112020015646A2 (pt) | Formulações intranasais de epinefrina e métodos para o tratamento de doença | |
| RS57740B1 (sr) | Ciklezonid za lečenje oboljenja disajnih puteva kod konja | |
| CA2653744C (en) | Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists | |
| D’Agnano et al. | Pharmacological treatment of interstitial lung diseases: a novel landscape for inhaled agents | |
| ES2706757T3 (es) | Formulación farmacéutica que comprende ciclesonida | |
| JP7369523B2 (ja) | 中等度～重度のインフルエンザの処置 | |
| TWI253930B (en) | Novel combination of loteprednol and beta2 adrenoceptor agonists | |
| AU2008296195A1 (en) | (DHEAS) inhalation compositions | |
| CN119654145A (zh) | 鼻内用巴氯芬 | |
| BRPI0616144A2 (pt) | composiÇço terapÊutica, uso de uma composiÇço terapÊutica,composiÇço farmacÊutica, e, uma primeira composiÇço terapÊutica compreendendo um composto s-nitrosotiol e uma segunda composiÇço terapÊutica compreendendo um segundo composto que nço o composto s-nitrosotiol | |
| JP2009506029A5 (enExample) |